Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2009: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2008: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Research Abstract |
The substances for the treatment of Alzheimer's disease, which decreased Aβ levels, were screened from clinically approved drugs. We identified KM2309 (code name, because of patent application). It inhibited γ-secretase and up-regulated a major Aβ-degrading enzyme neprilysin. Since it has been reported that KM2309 crosses the BBB and it has neuronal protective effect, KM2309 would be a novel drug candidate with safety for Alzheimer's disease.
|